Born and raised in Calgary, Alberta, Canada, Brad Sorenson is the founder and CEO of Providence Therapeutics.
In 2013, a stage four cancer diagnosis for Brad's teenage son set a course for Sorenson to dedicate his time and research towards eradicating the word "terminal" from any cancer diagnosis.
Brad's intimate journey with cancer eventually led him to the cutting-edge science of messenger RNA (mRNA), where in cooperation with physicians at The Alberta Children's Hospital, Brad developed a novel treatment protocol for his son, who is alive and thriving today.
Brad's passion for fighting terminal cancer outcomes and advocating for patient empowerment is captured through his work at Providence Therapeutics and his support for not-for-profit cancer foundations across Canada. His passion for building collaborations with a World-Class Canadian scientific team will continue to build a solid foundation for this biotech to grow on a global scale.